ovarian cancer

3 Companies Competing to Gain Lead in Ovarian Cancer Market
Yahoo/Zacks.com
Sat, 11/25/17 - 12:35 pm
ovarian cancer
AstraZeneca
Merck
Lynparza
Rubraca
Clovis Oncology
Zejula
Tesaro
AstraZeneca, Merck, Clovis and Tesaro, all vying for share, may all win on faster PARP growth
Fierce Pharma
Wed, 11/15/17 - 08:51 pm
AstraZeneca
Merck
Clovis Oncology
Tesaro
PARP inhibitors
ovarian cancer
Zejula
Rubraca
Lynparza
AstraZeneca, Tesaro and Clovis need to slash the cost of PARP meds, watchdog says
Fierce Pharma
Mon, 10/2/17 - 10:10 pm
AstraZeneca
Tesaro
Clovis Oncology
PARP inhibitors
drug pricing
ovarian cancer
Lynparza
Zejula
Rubraca
ESMO17: Clovis seeking new indication on positive ARIEL3 data
BioPharma Dive
Sun, 09/10/17 - 11:32 am
ESMO
Clovis Oncology
Rubraca
ovarian cancer
J&J Investors Should Ignore The Noise Of Cancer Lawsuits For Now
Seeking Alpha
Mon, 08/28/17 - 10:27 pm
JNJ
ovarian cancer
Here's Why Clovis Stock Is Up Almost 60% So Far in 2017
Yahoo/Zacks.com
Thu, 08/24/17 - 09:49 am
Clovis Oncology
Rubraca
ovarian cancer
Ovarian Cancer Market Still Up For Grabs
Barron's
Sat, 08/19/17 - 10:48 am
ovarian cancer
Lynparza
Tesaro
AstraZeneca
Clovis Oncology
Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
Yahoo/Zacks.com
Fri, 08/18/17 - 12:01 am
Pfizer
Bavencio
immuno-oncology
renal cell carcinoma
lung cancer
ovarian cancer
head and neck cancer
The Fastest Growing Cancer Company You've Never Heard Of
Motley Fool
Thu, 07/13/17 - 09:03 am
devices
Novocure
tumor treating fields
cancer
TTFields
glioblastoma
ovarian cancer
pancreatic cancer
lung cancer
AstraZeneca Is Focused on Lynparza’s Label Expansion in 2017
Market Realist
Mon, 07/10/17 - 11:39 am
AstraZenca
Lynparza
BRCA-mutated ovarian cancer
ovarian cancer
Here's Why Clovis Oncology Inc. Jumped 70% in June
Motley Fool
Fri, 07/7/17 - 08:33 am
Clovis Oncology
ovarian cancer
Rubraca
AstraZeneca Shares Progress on LYNPARZA™ (olaparib) Tablets in the US
Yahoo
Wed, 03/29/17 - 09:05 am
AstraZeneca
Lynparza
olaparib
ovarian cancer
Tesaro's PARP inhibitor approved in ovarian cancer
BioPharma Dive
Mon, 03/27/17 - 10:38 pm
Tesaro
ovarian cancer
PARP inhibitors
niraparib
AZ gears up for FDA filing as PARP inhibitor Lynparza wins big in ovarian cancer trial
Fierce Pharma
Tue, 03/14/17 - 04:43 pm
AstraZeneca
PARP inhibitors
Lynparza
FDA
ovarian cancer
clinical trials
Tesaro sees a $5B market opportunity for its cancer drug
Bizjournals.com
Fri, 02/17/17 - 10:14 am
Tesaro
niraparib
ovarian cancer
breast cancer
Clovis Oncology Secures FDA Approval for New Ovarian Cancer Drug
TheStreet.com
Mon, 12/19/16 - 11:51 am
Clovis Oncology
FDA
PARP inhibitors
rucaparib
ovarian cancer
Rubraca
As revenue falls, a pioneer of cancer gene testing slams rivals with overblown claims
Stat
Tue, 11/29/16 - 09:58 am
ovarian cancer
BRCA
Myriad Genetics
diagnostics
Immunovaccine’s targeted ovarian cancer therapy wins orphan drug status in EU
Drug Delivery Business
Tue, 11/22/16 - 09:52 pm
Immunovaccine
ovarian cancer
Europe
DPX-Survivac
After setback, Adaptimmune revamps T cell study
BioPharma Dive
Thu, 10/13/16 - 10:53 am
Adaptimmune
t cell therapy
NY-ESO SPEAR
ovarian cancer
These 3 Little Biotechs Just Scored Big
Motley Fool
Tue, 10/11/16 - 09:33 pm
biotech
Celldex Therapeutics
melanoma
glemba
Exelixis
Cabometyx
renal cell carcinoma
Tesaro
ovarian cancer
niraparib

Pages